Protagonist Therapeutics to Initiate Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with FDA and EMA

[Manouche]

« Protagonist Therapeutics (Nasdaq: PTGX) announced today that the Division of Nonmalignant Hematology at the U.S. Food and Drug Administration ("FDA") has provided important feedback during an End-of-Phase 2 meeting on rusfertide (PTG-300), an investigational new treatment for polycythemia vera ("PV"). Protagonist has also received written comments from the European Medicines Agency ("EMA") supportive of the Company's pivotal clinical development plan in PV »

streetinsider.com/dr/news.p...

[Kdavie12]

Thank you for posting, there is hope...

[JediReject]

Hi Manouche, , many Thanks for keeping us abreast of these latest developments. . It's good to know so much research is going on. Regards -Chris